AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis


  • AstraZeneca & BenevolentAI enter into an agreement to discover & develop therapies for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) utilizing artificial intelligence (AI) and machine learning
  • AstraZeneca will combine its genomics, chemistry and clinical data with Benevolent AI’s target identification platform and biomedical knowledge graph (network of genes, proteins, diseases and compounds) and will have insights of CKD and IPF diseases for identifying targets
  • Benevolent AI platform is a computational & experimental drug discovery platform which allows findings of pathways to treat disease and personalize drugs to patients focusing on four key areas: knowledge & reasoning, target identification, molecular design and precision medicine

Click here to read full press release/ article | Ref: AstraZeneca | Image: Royal Haskoning